Chris Brearley

Chris is one of tranScrip’s experts in Translational Medicine, Clinical Pharmacology and Early Development having clinical training in Internal Medicine, Nephrology and Clinical Pharmacology. Chris has worked in senior positions in Early Development for more than 30 years working in the UK, United States and Europe for Pfizer, Amgen and Serono before leading clinical development in Europe for Dainippon Sumitomo Pharma and then joining tranScrip in 2014.

Chris has extensive experience in working with biopharmaceutics and small molecules targeted across all therapeutic areas with a particular interest in neuroscience, immunology, inflammation, biomarker development, cardiovascular disease, nephrology and imaging.

Chris has been responsible for the design of, dose selection and risk mitigation, and medical oversight of multiple FIH studies and early development programmes. Chris has worked on monoclonal antibody, other biologic and small molecule-based approaches to asthma, cardiovascular disease, metabolic diseases and diabetes, COPD, atopic dermatitis, eczema, psoriasis, inflammatory bowel disease, lupus nephritis, COVID-19, stroke, Alzheimer’s disease (AD) and Parkinson’s disease (PD) together with rare diseases such as ADPKD, CF, ITP, myasthenia gravis, Gaucher’s disease and Niemann -Pick A/B Disease.

Chris has supported numerous PIPs from the strategic and clinical pharmacology perspectives, working most recently on PIPs for Hepatitis B/C and COVID-19. Chris has experience in neuroimaging studies to assess receptor occupancy and use as endpoints in stoke, AD and PD, and the use of such data to support clinical trial simulations.

He has extensive experience in supporting life-cycle management, the review of licensing opportunities and developing bridging strategies facilitating successful regulatory submissions in Japan, Korea and China as well as supporting successful regulatory interactions in the EU, US, China and Japan ranging from scientific advice to MMA/NDA and BLA.